KRAS and hepatocellular carcinoma: This study elucidates that pharmacological agent NSC48160 can precipitate ferroptosis and redox balance via modifications in their metabolic landscape, thereby impeding the proliferation of HCC cells via KRAS‐mediated ferroptosis, which is intricately linked with the regulatory triad of the Nrf2‐SLC7A11‐GPX4 signaling axis, employing both in vitro and in vivo methodologies, thus making it a potential therapeutic drug.